secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acorda Therapeutics, Inc. (—)
CIK:        0001008848
Form:       8-K
Filed at:   2024-04-04T23:59:59+00:00
Accession:  0000950170-24-041350
Event type: regulatory
Sentiment:  negative
Materiality: 0.90
Item codes: 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acorda Therapeutics receives Nasdaq delisting notice after Chapter 11 filing
----------------------------------------------------------------------------

- Nasdaq will suspend ACOR common stock at open on April 12, 2024, due to Chapter 11 filing and equity shortfall.
- Delisting follows the company's April 1 voluntary Chapter 11 petition and agreement with Merz Therapeutics to acquire substantially all assets.
- Company does not intend to appeal; expects stock to trade on the Pink Open Market after suspension.
- Nasdaq cited noncompliance with Listing Rules 5101, 5110(b), IM-5101-1, and failure to maintain at least $10M stockholders' equity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1008848/000095017024041350/0000950170-24-041350-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1008848/000095017024041350/acor-20240403.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-041350

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer